GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Journavx can be taken with ibuprofen for its anti-inflammatory effects. The prescription medication is not in pharmacies yet, but it maybe there by the end of February. Click here to report a typo.

"The Dupixent COPD clinical programme has furthered our scientific understanding of COPD, and given us a new way to think about which patients could benefit most from such a treatment. With its ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent—including agreements with payers and pharmacy benefit managers that ...